Vir Biotechnology

VIR BIOTECHNOLOGY INC

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Bonn,,Germany,January,03,2024:,Facade,Of,The,Bonn,Marriott

News

Markets

Analyst Ratings

Trading Ideas

MDCX

NEXN

NTLA

OCGN

TEVA

WULF

XRAY

Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday

cancer

Analyst Color

Biotech

Equities

Upgrades

Health Care

Price Target

General

Vir Biotechnology&#39;s Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety.

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here&#39;s Why

Movers

Vir Biotechnology&#39;s Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and PSMA in cancer therapies.

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here&#39;s Why

Vir Biotechnology Inc

Viratech Corp

Neuralbase AI Ltd

Virco Manufacturing Corporation - Common Stock

Virco Manufacturing Corp

Viridien

Pacer Funds Trust BioThreat Strategy ETF

Virtu Financial, Inc. Class A Common Stock

Virtu Financial Inc

VIRACTA THERAPEUTICS INC by Viracta Therapeutics, Inc.

Viracta Therapeutics Inc

Press Releases

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Earnings

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

BRIBY

AnaptysBio

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Cogent Biosciences

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Gyre Therapeutics

Immunome

Immatics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

MiMedx Group

Jyong Biotech

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Arcus Biosciences

Replimune Group

Sage Therapeutics

Sana Biotechnology

Sionna Therapeutics

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

Stoke Therapeutics

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Upstream Bio

Xencor

Zymeworks

Needham

Goldman Sachs

Barclays

HC Wainwright & Co.

Leerink Partners

Comments

Vir Biotechnology

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell